Peregrine Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Peregrine Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-411,436	Closed	-$13.7M	–	369
2020 Q2	$13.7M	Sell	411,436 -61,110	-13%	-$1.95M	0.39%	105
2020 Q1	$12.9M	Sell	472,546 -278,087	-37%	-$7.74M	0.46%	88
2019 Q4	$14.8M	Sell	750,633 -81,994	-10%	-$1.31M	0.38%	117
2019 Q3	$10.8M	Buy	832,627 +27,377	+3%	+$331K	0.29%	138
2019 Q2	$10M	Buy	+805,250	New	+$10.7M	0.25%	154

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Peregrine Capital Management's MNTA Position: Q3 2020 in Review

Peregrine Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 411,436 shares — an estimated $13.7M sold.

Peregrine Capital Management first reported a position in MNTA in Q2 2019 and held it in 5 quarters. The position peaked at $14.8M in Q4 2019. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

Peregrine Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Peregrine Capital Management sold 411,436 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $13.7M.
Peregrine Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2019 and held it in 5 quarters.
Peregrine Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $14.8M in Q4 2019.
211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Peregrine Capital Management's 13F filing for Q3 2020, filed 20 Oct 2020.